VBIO
Income statement / Annual
Last year (2021), Valion Bio Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2021, Valion Bio Inc.'s net income was -$880.85 K.
See Valion Bio Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
03/31/2015 |
03/31/2014 |
03/31/2013 |
03/31/2012 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$102.42 K |
$163.36 K |
$248.35 K |
$245.68 K |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$77.94 K
|
$108.26 K
|
$149.48 K
|
$121.34 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$24.48 K
|
$55.10 K
|
$98.87 K
|
$124.34 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0.24
|
0.34
|
0.4
|
0.51
|
0
|
0
|
0
|
| Research and Development Expenses |
$408.91 K
|
$1.01 M
|
$1.74 M
|
$1.90 M
|
$893.96 K
|
$613.12 K
|
$1.13 M
|
$580.00 K
|
$250.00 K
|
$0.00
|
| General & Administrative Expenses |
$1.93 M
|
$2.68 M
|
$2.82 M
|
$2.52 M
|
$2.63 M
|
$2.23 M
|
$2.80 M
|
$3.02 M
|
$2.29 M
|
$1.26 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.93 M
|
$2.68 M
|
$2.82 M
|
$2.52 M
|
$2.63 M
|
$2.23 M
|
$2.80 M
|
$3.02 M
|
$2.29 M
|
$1.26 M
|
| Other Expenses |
$0.00
|
$0.00
|
$1.37 M
|
-$8.00
|
-$3.00
|
$0.00
|
-$3.00
|
-$2.41 K
|
$8.97 K
|
$2.34 K
|
| Operating Expenses |
$2.34 M
|
$3.69 M
|
$5.94 M
|
$4.42 M
|
$3.53 M
|
$2.84 M
|
$3.93 M
|
$3.60 M
|
$2.55 M
|
$1.26 M
|
| Cost And Expenses |
$2.34 M
|
$3.69 M
|
$4.57 M
|
$4.50 M
|
$3.63 M
|
$2.99 M
|
$4.05 M
|
$3.60 M
|
$2.44 M
|
$1.30 M
|
| Interest Income |
$0.00
|
$1.25 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$6.78 K
|
$0.00
|
$1.01 K
|
$363.00
|
$6.07 K
|
$404.32 K
|
$425.37 K
|
$18.30 K
|
| Depreciation & Amortization |
$1.46 M
|
$0.00
|
$12.27 K
|
$87.75 K
|
$0.00
|
$2.60 M
|
$0.00
|
$0.00
|
$125.37 K
|
$0.00
|
| EBITDA |
-$880.85 K |
-$3.69 M |
-$4.43 M |
-$4.31 M |
-$5.22 M |
-$140.97 K |
-$4.04 M |
-$3.75 M |
-$2.31 M |
-$1.30 M |
| EBITDA Ratio |
0
|
0
|
0
|
-42.07
|
-31.94
|
-0.57
|
-16.45
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
-42.93
|
-21.25
|
-11.04
|
-15.49
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.46 M
|
$60.48 K
|
$117.33 K
|
$87.75 K
|
-$1.75 M
|
$2.60 M
|
-$243.21 K
|
-$550.00 K
|
-$300.00 K
|
-$20.00 K
|
| Income Before Tax |
-$880.85 K
|
-$3.63 M
|
-$4.45 M
|
-$4.31 M
|
-$5.22 M
|
-$141.33 K
|
-$4.05 M
|
-$4.15 M
|
-$2.74 M
|
-$1.32 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-42.07
|
-31.95
|
-0.57
|
-16.48
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$733.13 K
|
$124.11 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$880.85 K
|
-$4.37 M
|
-$20.14 M
|
-$4.31 M
|
-$5.22 M
|
-$141.33 K
|
-$4.05 M
|
-$4.15 M
|
-$2.74 M
|
-$1.32 M
|
| Net Income Ratio |
0
|
0
|
0
|
-42.07
|
-31.95
|
-0.57
|
-16.48
|
0
|
0
|
0
|
| EPS |
-0.0173 |
-0.0859 |
-0.61 |
-0.19 |
-0.38 |
-0.0187 |
-0.57 |
-0.69 |
-0.51 |
-0.26 |
| EPS Diluted |
-0.0173 |
-0.0859 |
-0.61 |
-0.19 |
-0.38 |
-0.0187 |
-0.57 |
-0.69 |
-0.51 |
-0.0255 |
| Weighted Average Shares Out |
$50.84 M
|
$50.84 M
|
$33.00 M
|
$23.12 M
|
$13.59 M
|
$7.54 M
|
$7.04 M
|
$6.01 M
|
$5.34 M
|
$6.35 M
|
| Weighted Average Shares Out Diluted |
$50.84 M
|
$50.84 M
|
$33.00 M
|
$23.12 M
|
$13.59 M
|
$7.54 M
|
$7.04 M
|
$6.01 M
|
$5.34 M
|
$51.70 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
